Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5Unknown 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 20Gastrointestinal 10Head & Neck 9CNS 9Genitourinary 6Tumor-Agnostic 5Sarcoma 5Endocrine 4Breast 4Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Adenocarcinoma 2

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × vandetanib × Tumor-Agnostic × Clear all
NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00500292 2018-01-25

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Sanofi

Phase 2 Completed
109 enrolled 8 charts
Tumor-Agnostic

Neoplasms

NCT00503711 2016-08-31

Phase I Chinese PK

Sanofi

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

NCT00499850 2016-08-25

Phase I FOLFOX Combination

Sanofi

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT00507091 2016-08-25

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Sanofi

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡